Novavax's stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for the year ...

The Novavax logo displayed on a smartphone screen ... referring to the contract with Sanofi. Novavax also announced another, ...

The program taps into several OpenAI models and can be used across a wide range of therapeutic indications. Both Big Pharma ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

Healx will use its AI-based drug discovery tech to analyze proprietary Sanofi compound data and identify potential rare disease targets.

Further boosting the pipeline, mid-stage drugs like Sanofi/Regeneron’s itepekimab, AstraZeneca’s benralizumab, Amgen Inc ...

We speak with Mohammed Charki, who knows a lot about partnerships between pharma and biotech, as he is currently “on loan” from Sanofi with start-up biotech Hemarina, where he is advising and ...

Yuichi Iwaki, M.D., Ph.D., MediciNova CEO commented, “The successful resolution of the Sanofi-Novartis litigation and the resulting monetary damages due to MediciNova both validates the value of our ...

DelveInsight's 'Multiple Sclerosis Pipeline Insight 2024' report provides comprehensive global coverage of pipeline multiple ...

Nov 12 (Reuters) - Novavax (NVAX.O), opens new tab cut its annual revenue forecast on Tuesday, citing lower-than-expected ...

However, Paul Hudson, CEO of Sanofi, one of the world's leading biopharmaceutical companies, says executives may need to rein ...

Novavax has made a smaller splash in the U.S. Covid-19 vaccine market than it had hoped. But it's betting on licensing deals ...